Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ ADARB1 Polyclonal Antibody
GREENER_CHOICE

Catalog No. PIPA5101139
Change view
Click to view available options
Quantity:
100 μL
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIPA5101139 100 μL
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. PIPA5101139 Supplier Invitrogen™ Supplier No. PA5101139
Add to Cart
Add to Cart

Rabbit Polyclonal Antibody

Antibody detects endogenous levels of total ADARB1.

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis.
TRUSTED_SUSTAINABILITY

Specifications

Antigen ADARB1
Applications Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry
Classification Polyclonal
Concentration 1 mg/mL
Conjugate Unconjugated
Formulation PBS with 50% glycerol and 0.02% sodium azide; pH 7.4
Gene ADARB1
Gene Accession No. P51400, P78563, Q91ZS8
Gene Alias 1700057H01Rik; Adar2; Adarb1; adenosine deaminase, RNA specific B1; adenosine deaminase, RNA-specific, B1; adenosine deaminase, RNA-specific, B1 (homolog of rat RED1); adenosine deaminase, RNA-specific, B1 (RED1 homolog rat); AW124433; AW558573; BB220382; D10Bwg0447e; Double-stranded RNA-specific editase 1; DRABA2; DRADA2; dsRNA adenosine deaminase; dsRNA adenosine deaminase DRADA2; Red1; RED1 homolog; RNA editase; RNA editing deaminase 1; RNA editing deaminase of glutamate receptors; RNA-editing deaminase 1; RNA-editing enzyme 1
Gene Symbols ADARB1
Host Species Rabbit
Immunogen A synthesized peptide derived from human ADARB1(Accession P78563), corresponding to amino acid residues L490-Q540.
Purification Method Affinity chromatography
Quantity 100 μL
Regulatory Status RUO
Primary or Secondary Primary
Gene ID (Entrez) 104, 110532, 25367
Target Species Human, Mouse, Rat
Content And Storage -20°C
Product Type Antibody
Form Liquid
Isotype IgG
Show More Show Less
WARNING: Cancer - www.P65Warnings.ca.gov
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.